Trimurthi Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 10-12-2024
- Paid Up Capital ₹ 5.00 M
as on 10-12-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.66 M
as on 10-12-2024
- Revenue 72.27%
(FY 2022)
- Profit -835.84%
(FY 2022)
- Ebitda -1712.35%
(FY 2022)
- Net Worth -45.39%
(FY 2022)
- Total Assets 19.52%
(FY 2022)
About Trimurthi Pharmaceuticals (India)
The Corporate was formerly known as Skf Lifescience Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.66 M.
Arvind Bhangadia and Aditya Bhangadia serve as directors at the Company.
- CIN/LLPIN
U24232TG2012PTC080276
- Company No.
080276
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
- Apps
Who are the key members and board of directors at Trimurthi Pharmaceuticals (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Bhangadia  | Director | 12-Apr-2012 | Current |
| Arvind Bhangadia | Whole-Time Director | 01-Jun-2015 | Current |
Financial Performance and Corporate Structure Insights of Trimurthi Pharmaceuticals (India).
Trimurthi Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 72.27% increase. The company also saw a substantial fall in profitability, with a 835.84% decrease in profit. The company's net worth observed a substantial decline by a decrease of 45.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trimurthi Pharmaceuticals (India)?
In 2022, Trimurthi Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Apr 2022 | ₹1.66 M | Open |
How Many Employees Work at Trimurthi Pharmaceuticals (India)?
Unlock and access historical data on people associated with Trimurthi Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trimurthi Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trimurthi Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
